Erratum to: Do We Need another Antiangiogenesis Agent for Colorectal Cancer: are Bevacizumab and Aflibercept the Same?

Maria Ignez Braghiroli · Rachel P. Riechelmann ·
Jorge Sabbaga · Paulo M. Hoff

Published online: 28 May 2014
© Springer Science+Business Media New York 2014

Erratum to: Curr Colorectal Cancer Rep (2013) 9:317–325
DOI 10.1007/s11888-013-0187-0

The original version of this article, published in *Current Colorectal Cancer Reports*, Volume 9, Issue 4, December 2013, contained a misprint in Table 1, “Comparison of bevacizumab and aflibercept.” Under “Dose and association in colorectal cancer,” the dosing unit for bevacizumab was given in “mg/m⁻²,” when it should be “mg/kg.” The table provided is now correct.

The online version of the original article can be found at <http://dx.doi.org/10.1007/s11888-013-0187-0>.

M. I. Braghiroli (✉) · R. P. Riechelmann · J. Sabbaga · P. M. Hoff
Centro de Oncologia do Hospital Sírio Libanês, Rua D. Adma Jafet,
91, Bela Vista CEP, 01308-050 São Paulo, SP, Brazil
e-mail: ignezbraghiroli@gmail.com

R. P. Riechelmann
e-mail: rachel.riechelmann@icesp.org.br

J. Sabbaga
e-mail: jsabbaga@uol.com.br

P. M. Hoff
e-mail: paulo.hoff@icesp.org.br

M. I. Braghiroli · J. Sabbaga · P. M. Hoff
Instituto de Câncer do Estado de São Paulo do Hospital das Clínicas
da Faculdade de Medicina de Universidade de São Paulo, Av. Doutor
Amaldo, 251, Oncologia Clínica 5º andar, Cerqueira César CEP,
01246-000 São Paulo, SP, Brazil

Table 1 Comparison of bevacizumab and aflibercept

	Bevacizumab	Aflibercept
Description	Humanized monoclonal immunoglobulin G antibody	Fully humanized soluble recombinant fusion protein with domains from VEGFR-1 and VEGFR-2
Target	VEGF-A	VEGF-A, VEGF-B, PIGF
Molecular weight	149 kD	115 kD
Dose and association in colorectal cancer	5-10 mg/kg, IV, every 2 weeks with FOLFOX or FOLFIRI	4 mg/kg every 2 weeks with FOLFIRI
Relevant adverse events	Hemorrhage, thrombosis, proteinuria, hypertension, GI perforation	Hemorrhage, hand-foot syndrome, hypertension, fatigue
Worsening chemotherapy side effects	No	Yes, specially diarrhea, neutropenia, stomatitis
Positive Phase III Trials	First Line: IFL+/- bevacizumab FOLFOX/XELOX +/- bevacizumab Second Line: FOLFOX +/- bevacizumab Chemotherapy +/- bevacizumab after progression on bevacizumab	Second Line FOLFIRI +/- aflibercept